Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Cancers|March 13, 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Rebeca Rodriguez-Veiga, Claudia Sargas, et al.
Blood|November 5, 2020
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemiaJosep-Maria Ribera, Mireia Morgades, Juana Ciudad, et al.
Leukemia|September 1, 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso-Pierola, David Martinez-Cuadrón, Rebeca Rodríguez-Veiga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, et al.
Leukemia & Lymphoma|July 22, 2021
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA groupTomás Palanques-Pastor, Juan Eduardo Megías-Vericat, Pilar Martínez, et al.
Haematologica|July 16, 2026
Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter studyJosé Vicente Gil, Claudia Sargas, Rosa Ayala, et al.
Haematologica|May 14, 2026
Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI studyPilar Lloret-Madrid, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, et al.
American Journal of Hematology|April 22, 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA StudyGaspar Aspas Requena, Rebeca Rodríguez-Veiga, Cristina Gil, et al.
Blood|June 8, 2026
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA studyJosé Vicente Gil, Claudia Sargas, Rosa Ayala, et al.
Blood Neoplasia|June 15, 2026
Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry studyEva Barragán, José Vicente Gil, Rosa Ayala, et al.
Pageof 9